Abstract:
Immune checkpoint inhibitors (ICIs) constitute a new class of anti-tumor drugs widely used in clinical practice. However, immune toxicity occurs when ICI-induced activation of the immune system leads to damage of the normal organs of the human body. This type of immune damage can affect any part of the body and can cause symptoms known as immunocheckpoint inhibitors related adverse effects (irAEs). Glucocorticoid is the mainstay of treatment for liver injury. However, ways of managing grade ≥3 liver injury and preventing the development of hormone resistance remain unclear. We described two cases of liver injury after immunotherapy: one patient was corticosteroid-sensitive, while the other was corticosteroid-resistant and received salvage treatment with immunoglobulin.